Kilter Group’s Axsome Therapeutics AXSM Stock Holding History

Kilter Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.47K	Buy	6 +5	+500%	+$1.08K	﹤0.01%	1147
2026 Q1	$170	Buy	+1	New	+$173	﹤0.01%	1491

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kilter Group's AXSM Position: Q2 2026 in Review

Kilter Group increased its Axsome Therapeutics (AXSM) stake by 500% in Q2 2026, buying an estimated $1.08K and bringing the position to 6 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

Kilter Group first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Kilter Group held 6 shares of Axsome Therapeutics worth $1.47K as of Q2 2026.
Kilter Group bought 5 Axsome Therapeutics shares in Q2 2026, an estimated $1.08K.
Axsome Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1147 holding.
Kilter Group first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.